政策引导、需求刺激 民营医疗市场发展迅速

2018-03-30 佚名 前瞻产业研究院

随着经济水平的不断提升,民众的医疗需求也呈现扩大化、多样化的态势,而有实力的公立医院所能提供的就医资源有限,大城市里往往一号难求,这给民营医院带来了较大的发展机遇。同时,随着更注重预防保健和对就医体验有更高要求的高端医疗市场消费群体扩增,民营医院有能力去高薪聘用专家以及提供舒适的就医环境来满足高端消费群体个性化的就医需求。

随着经济水平的不断提升,民众的医疗需求也呈现扩大化、多样化的态势,而有实力的公立医院所能提供的就医资源有限,大城市里往往一号难求,这给民营医院带来了较大的发展机遇。同时,随着更注重预防保健和对就医体验有更高要求的高端医疗市场消费群体扩增,民营医院有能力去高薪聘用专家以及提供舒适的就医环境来满足高端消费群体个性化的就医需求。

收入增长与医保覆盖扩大推动我国医疗服务市场规模持续增长

年来,随着国民经济的发展,我国居民可支配收入水平持续上升,公众的健康意识也在不断增强,使得我国居民对医疗服务的消费能力和消费需求得到了有效提升。

另一方面,我国的城镇职工医疗保险制度、城镇居民医疗保险制度和新型农村合作医疗保险制度相继建立并不断完善,大大提升了患者及其家属对医疗费用的支付能力。

受此推动,我国医疗服务需求持续增长,医疗服务市场规模不断扩大,根据政府有关部门的规划目标,在未来仍将保持持续较快的增长。

根据前瞻产业研究院发布的《中国民营医疗行业市场前瞻与投资战略规划分析报告》数据显示,我国包括政府卫生支出、社会卫生支出及个人卫生支出在内的卫生总费用由 2010 年的 19,980.39 亿元增至 2015 年的 40,974.64 亿元,年均复合增长率为 15.45%。卫生总费用占我国 GDP 的比重也不断提升,从 2010 年的4.84%增长至 2015 年的 5.98%。卫生部组织研究发布的《“健康中国 2020”战略研究报告》提出“到 2020 年,主要健康指标基本达到中等发达国家水平”,其包括的 10 个具体目标之一即为到 2020 年,卫生总费用占 GDP 的比重达到6.5%-7.0%,未来我国医疗卫生支出在国民经济中的重要性将得到进一步提升。

我国卫生总费用及其占GDP比重情况


数据来源:前瞻产业研究院整理

中国民营医院数量预测

据前瞻产业研究院数据统计,截至2014年11月底,我国民营医院数量为12,166个,与2013年同期相比增加了约10.31%。截至2015年11月底,我国民营医院数量为14,049个,与2014年同期相比增加了约15.48%。截至2016年6月底,我国民营医院数量为15,303个,与2015年同期相比增加了约16.35%。预计2017年我国民营医院数量将达到1.9万个,未来五年(2017-2021)年均复合增长率约为20.42%,2021年数量将达到4.6万个。

民营医院数量


数据来源:前瞻产业研究院整理

据前瞻产业研究院统计,医疗服务需求的持续快速增长,与老龄人口的增长有更为密切的关系。截至2014 年底我国65 岁以上的老龄人口已超过1.3 亿,比例达到10.1%,我国已成为世界上老龄人口最多的国家。根据《国家应对人口老龄化战略研究》课题组的估计,2025年老龄人口将突破3 亿。北京大学国家发展研究院研究表明,65 岁以上老年人口组的年均医疗费用远远高于其他组别的人群,这也说明老龄人口对医疗服务消费较其他组别有更明显的推动作用。

政策引导和需求刺激下民营医疗机构迅速发展

近年来,我国民众的医疗服务需求不断增长,但公立医院的医疗卫生资源有限且高度集中在城市。随着我国医药卫生体制改革的不断深化,政府提出了多项政策意见鼓励社会资本进入医疗领域。报告提出,到 2020 年,按照每千常住人口不低于 1.5 张床位为社会办医院预留规划空间,同步预留诊疗科目设置和大型医用设备配置空间,为社会资本进入医疗卫生服务行业创造了良好环境。

由于具备融资渠道广、管理机制灵活、提供市场化服务等特征,民营医院发展迅速,在医疗服务行业中能够发挥日益重要的作用。首先表现为数量迅速增长,我国民营医院数量从 2010 年底的 7,068 家增加至 2015 年底的 14,518 家,年均复合增长率为 15.5%,占医院总数比重从33.8%上升至52.6%。与此同时,公立医院数量从13,850家下降至13,069家,公立医院数量占医院总数比重从 66.2%下降至 47.4%。

公立医院、民营医院数量变化情况


资料来源:公开资料整理

民营资本进入医疗服务领域,将形成以公立医疗机构为主体,民营医疗机构为补充的多元医疗服务格局,从而更好的满足人们日益增长的医疗服务需求,通过引入竞争促进医疗服务行业健康发展。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2056400, encodeId=16cb2056400a6, content=<a href='/topic/show?id=541163e44cb' target=_blank style='color:#2F92EE;'>#民营医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63744, encryptionId=541163e44cb, topicName=民营医疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sat Jul 21 10:27:00 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981528, encodeId=353a1981528d2, content=<a href='/topic/show?id=ef6f483422a' target=_blank style='color:#2F92EE;'>#市场发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48342, encryptionId=ef6f483422a, topicName=市场发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Fri Jun 15 14:27:00 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736072, encodeId=26301e36072af, content=<a href='/topic/show?id=56443493978' target=_blank style='color:#2F92EE;'>#医疗市场#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34939, encryptionId=56443493978, topicName=医疗市场)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12fc34051956, createdName=lsj639, createdTime=Sat Nov 10 04:27:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752528, encodeId=3aa21e52528d0, content=<a href='/topic/show?id=1bbd63e40fd' target=_blank style='color:#2F92EE;'>#民营#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63740, encryptionId=1bbd63e40fd, topicName=民营)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0c36549805, createdName=chaojitidian, createdTime=Mon Dec 10 07:27:00 CST 2018, time=2018-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260322, encodeId=078f126032268, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sun Apr 01 11:27:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301287, encodeId=0a2d30128e6e, content=好好学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Fri Mar 30 22:38:25 CST 2018, time=2018-03-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2056400, encodeId=16cb2056400a6, content=<a href='/topic/show?id=541163e44cb' target=_blank style='color:#2F92EE;'>#民营医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63744, encryptionId=541163e44cb, topicName=民营医疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sat Jul 21 10:27:00 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981528, encodeId=353a1981528d2, content=<a href='/topic/show?id=ef6f483422a' target=_blank style='color:#2F92EE;'>#市场发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48342, encryptionId=ef6f483422a, topicName=市场发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Fri Jun 15 14:27:00 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736072, encodeId=26301e36072af, content=<a href='/topic/show?id=56443493978' target=_blank style='color:#2F92EE;'>#医疗市场#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34939, encryptionId=56443493978, topicName=医疗市场)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12fc34051956, createdName=lsj639, createdTime=Sat Nov 10 04:27:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752528, encodeId=3aa21e52528d0, content=<a href='/topic/show?id=1bbd63e40fd' target=_blank style='color:#2F92EE;'>#民营#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63740, encryptionId=1bbd63e40fd, topicName=民营)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0c36549805, createdName=chaojitidian, createdTime=Mon Dec 10 07:27:00 CST 2018, time=2018-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260322, encodeId=078f126032268, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sun Apr 01 11:27:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301287, encodeId=0a2d30128e6e, content=好好学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Fri Mar 30 22:38:25 CST 2018, time=2018-03-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2056400, encodeId=16cb2056400a6, content=<a href='/topic/show?id=541163e44cb' target=_blank style='color:#2F92EE;'>#民营医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63744, encryptionId=541163e44cb, topicName=民营医疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sat Jul 21 10:27:00 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981528, encodeId=353a1981528d2, content=<a href='/topic/show?id=ef6f483422a' target=_blank style='color:#2F92EE;'>#市场发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48342, encryptionId=ef6f483422a, topicName=市场发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Fri Jun 15 14:27:00 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736072, encodeId=26301e36072af, content=<a href='/topic/show?id=56443493978' target=_blank style='color:#2F92EE;'>#医疗市场#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34939, encryptionId=56443493978, topicName=医疗市场)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12fc34051956, createdName=lsj639, createdTime=Sat Nov 10 04:27:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752528, encodeId=3aa21e52528d0, content=<a href='/topic/show?id=1bbd63e40fd' target=_blank style='color:#2F92EE;'>#民营#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63740, encryptionId=1bbd63e40fd, topicName=民营)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0c36549805, createdName=chaojitidian, createdTime=Mon Dec 10 07:27:00 CST 2018, time=2018-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260322, encodeId=078f126032268, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sun Apr 01 11:27:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301287, encodeId=0a2d30128e6e, content=好好学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Fri Mar 30 22:38:25 CST 2018, time=2018-03-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2056400, encodeId=16cb2056400a6, content=<a href='/topic/show?id=541163e44cb' target=_blank style='color:#2F92EE;'>#民营医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63744, encryptionId=541163e44cb, topicName=民营医疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sat Jul 21 10:27:00 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981528, encodeId=353a1981528d2, content=<a href='/topic/show?id=ef6f483422a' target=_blank style='color:#2F92EE;'>#市场发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48342, encryptionId=ef6f483422a, topicName=市场发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Fri Jun 15 14:27:00 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736072, encodeId=26301e36072af, content=<a href='/topic/show?id=56443493978' target=_blank style='color:#2F92EE;'>#医疗市场#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34939, encryptionId=56443493978, topicName=医疗市场)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12fc34051956, createdName=lsj639, createdTime=Sat Nov 10 04:27:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752528, encodeId=3aa21e52528d0, content=<a href='/topic/show?id=1bbd63e40fd' target=_blank style='color:#2F92EE;'>#民营#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63740, encryptionId=1bbd63e40fd, topicName=民营)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0c36549805, createdName=chaojitidian, createdTime=Mon Dec 10 07:27:00 CST 2018, time=2018-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260322, encodeId=078f126032268, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sun Apr 01 11:27:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301287, encodeId=0a2d30128e6e, content=好好学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Fri Mar 30 22:38:25 CST 2018, time=2018-03-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2056400, encodeId=16cb2056400a6, content=<a href='/topic/show?id=541163e44cb' target=_blank style='color:#2F92EE;'>#民营医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63744, encryptionId=541163e44cb, topicName=民营医疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sat Jul 21 10:27:00 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981528, encodeId=353a1981528d2, content=<a href='/topic/show?id=ef6f483422a' target=_blank style='color:#2F92EE;'>#市场发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48342, encryptionId=ef6f483422a, topicName=市场发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Fri Jun 15 14:27:00 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736072, encodeId=26301e36072af, content=<a href='/topic/show?id=56443493978' target=_blank style='color:#2F92EE;'>#医疗市场#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34939, encryptionId=56443493978, topicName=医疗市场)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12fc34051956, createdName=lsj639, createdTime=Sat Nov 10 04:27:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752528, encodeId=3aa21e52528d0, content=<a href='/topic/show?id=1bbd63e40fd' target=_blank style='color:#2F92EE;'>#民营#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63740, encryptionId=1bbd63e40fd, topicName=民营)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0c36549805, createdName=chaojitidian, createdTime=Mon Dec 10 07:27:00 CST 2018, time=2018-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260322, encodeId=078f126032268, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sun Apr 01 11:27:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301287, encodeId=0a2d30128e6e, content=好好学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Fri Mar 30 22:38:25 CST 2018, time=2018-03-30, status=1, ipAttribution=)]
    2018-04-01 bioon3
  6. [GetPortalCommentsPageByObjectIdResponse(id=2056400, encodeId=16cb2056400a6, content=<a href='/topic/show?id=541163e44cb' target=_blank style='color:#2F92EE;'>#民营医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63744, encryptionId=541163e44cb, topicName=民营医疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sat Jul 21 10:27:00 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981528, encodeId=353a1981528d2, content=<a href='/topic/show?id=ef6f483422a' target=_blank style='color:#2F92EE;'>#市场发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48342, encryptionId=ef6f483422a, topicName=市场发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Fri Jun 15 14:27:00 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736072, encodeId=26301e36072af, content=<a href='/topic/show?id=56443493978' target=_blank style='color:#2F92EE;'>#医疗市场#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34939, encryptionId=56443493978, topicName=医疗市场)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12fc34051956, createdName=lsj639, createdTime=Sat Nov 10 04:27:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752528, encodeId=3aa21e52528d0, content=<a href='/topic/show?id=1bbd63e40fd' target=_blank style='color:#2F92EE;'>#民营#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63740, encryptionId=1bbd63e40fd, topicName=民营)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0c36549805, createdName=chaojitidian, createdTime=Mon Dec 10 07:27:00 CST 2018, time=2018-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260322, encodeId=078f126032268, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sun Apr 01 11:27:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301287, encodeId=0a2d30128e6e, content=好好学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Fri Mar 30 22:38:25 CST 2018, time=2018-03-30, status=1, ipAttribution=)]
    2018-03-30 忠诚向上

    好好学习天天向上

    0

相关资讯

人社部:全国开展按病种付费,不少于100个!

按病种付费又有了新消息!人社部推荐了130个病种,要求各地应确定不少于100个开展按病种付费。

重磅!医院炮制中药制剂,只需备案

随着新年的脚步声,好消息一茬接着一茬!国家食品药品监督管理总局发布重磅消息,医院传统中药制剂实行备案制管理!

刚刚!匹多莫德被降辅助药,三岁以下禁用!

你家宝宝吃过匹多莫德吗? 匹多莫德多用于儿科,用来预防感冒、发烧咳嗽、鼻炎扁桃体炎等疾病。

国家卫计委发文 药品招标不合理管制或被废止

全国各地具有地方特色的药品招标管制等政策,2018年将面临重大调整甚至废止。

区域检验中心来了,不是狼,而是鲶鱼!

据悉,历时近三年,首部《基本医疗卫生与健康促进法(草案)》(下称《草案》),已于近日交由十二届全国人大常委会初次审议。在总则部分草案首次在法律层面上直接提出健康是人的基本权益,以及国家实施健康中国战略;《草案》还明确规定,医疗卫生机构应以公立医疗卫生机构为主导,要坚持非营利性医疗机构为主体、营利性医疗机构为补充的总体布局,并且政府办公立医疗卫生机构,不得与社会资本合作举办营利性机构,且公立医院不得

ISC2018:AHA主席呼吁从影响政策、系统和环境变化,来共同抗击卒中!

美国当地时间1月24日,2018年国际卒中大会(International Stroke Conference)在美国加利福尼亚州洛杉矶会议中心隆重开幕。来自世界各地卒中领域的4500余名同道共聚一堂,共商卒中防治大计。